Oliver J. McElvaney

2.6k total citations · 1 hit paper
41 papers, 1.2k citations indexed

About

Oliver J. McElvaney is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Oliver J. McElvaney has authored 41 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 13 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Oliver J. McElvaney's work include Cystic Fibrosis Research Advances (19 papers), Neonatal Respiratory Health Research (14 papers) and Protease and Inhibitor Mechanisms (13 papers). Oliver J. McElvaney is often cited by papers focused on Cystic Fibrosis Research Advances (19 papers), Neonatal Respiratory Health Research (14 papers) and Protease and Inhibitor Mechanisms (13 papers). Oliver J. McElvaney collaborates with scholars based in Ireland, United States and United Kingdom. Oliver J. McElvaney's co-authors include Noel G. McElvaney, Emer P. Reeves, Gerard F. Curley, David A. Bergin, Stefan Rose‐John, Tomás P. Carroll, Michael Henry, Paula Meleady, Martin Clynes and Cedric Gunaratnam and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Oliver J. McElvaney

40 papers receiving 1.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-6: obstacles to targeting a complex cytokine in critical illness

2021 155 citations Oliver J. McElvaney, Gerard F. Curley et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver J. McElvaney Ireland	18	537	288	258	249	161	41	1.2k
Mirjam E. Belderbos Netherlands	19	357 0.7×	301 1.0×	198 0.8×	271 1.1×	105 0.7×	39	1.3k
Takahisa Suzuki Japan	20	368 0.7×	305 1.1×	101 0.4×	201 0.8×	233 1.4×	160	1.5k
Borko Jovanovic United States	19	221 0.4×	179 0.6×	115 0.4×	229 0.9×	215 1.3×	34	1.5k
D. Maroeska W. M. te Loo Netherlands	22	178 0.3×	297 1.0×	93 0.4×	310 1.2×	219 1.4×	73	1.5k
Yubiao Guo China	16	401 0.7×	295 1.0×	134 0.5×	225 0.9×	90 0.6×	70	1.1k
Ana Lúcia Coelho United States	23	664 1.2×	621 2.2×	170 0.7×	681 2.7×	214 1.3×	44	1.9k
Fabian Finkelmeier Germany	22	403 0.8×	381 1.3×	257 1.0×	324 1.3×	584 3.6×	81	1.7k
C. Belleguic France	15	520 1.0×	174 0.6×	143 0.6×	128 0.5×	133 0.8×	41	1.2k
Sílvia Helena Barem Rabenhorst Brazil	19	153 0.3×	348 1.2×	125 0.5×	115 0.5×	207 1.3×	89	1.0k

Countries citing papers authored by Oliver J. McElvaney

Since Specialization

Citations

This map shows the geographic impact of Oliver J. McElvaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver J. McElvaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver J. McElvaney more than expected).

Fields of papers citing papers by Oliver J. McElvaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver J. McElvaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver J. McElvaney. The network helps show where Oliver J. McElvaney may publish in the future.

Co-authorship network of co-authors of Oliver J. McElvaney

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver J. McElvaney. A scholar is included among the top collaborators of Oliver J. McElvaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver J. McElvaney. Oliver J. McElvaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kapnadak, Siddhartha G., Oliver J. McElvaney, Jordan Dunitz, et al.. (2024). Attitudes toward and preparedness for lung transplantation among individuals with cystic fibrosis in the era of highly effective modulators. BMC Pulmonary Medicine. 24(1). 348–348. 2 indexed citations

McElvaney, Oliver J. & Graham T. McMahon. (2024). International Medical Graduates and the Physician Workforce. JAMA. 332(6). 490–490. 6 indexed citations

McElvaney, Oliver J., Brian Cleary, Oisín F. McElvaney, et al.. (2023). Safety and Reactogenicity of COVID-19 Vaccination in Severe Alpha-1 Antitrypsin Deficiency. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 11(1). 3–12. 3 indexed citations

McElvaney, Oliver J., Sonya L. Heltshe, Katherine Odem‐Davis, et al.. (2023). Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis. Journal of Cystic Fibrosis. 22(5). 875–879. 5 indexed citations

Clarke, Jennifer, Pierce Geoghegan, Natalie McEvoy, et al.. (2021). Prone positioning improves oxygenation and lung recruitment in patients with SARS-CoV-2 acute respiratory distress syndrome; a single centre cohort study of 20 consecutive patients. BMC Research Notes. 14(1). 20–20. 19 indexed citations

Palmas, Francesco, Jennifer Clarke, Romain A. Colas, et al.. (2021). Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. PLoS ONE. 16(8). e0256226–e0256226. 33 indexed citations

Hogan, Grace, Pierce Geoghegan, Tomás P. Carroll, et al.. (2021). α1-Antitrypsin: Key Player or Bystander in Acute Respiratory Distress Syndrome?. Anesthesiology. 134(5). 792–808. 7 indexed citations

McElvaney, Oliver J., Gerard F. Curley, Stefan Rose‐John, & Noel G. McElvaney. (2021). Interleukin-6: obstacles to targeting a complex cytokine in critical illness. The Lancet Respiratory Medicine. 9(6). 643–654. 155 indexed citations breakdown →

McElvaney, Oliver J., Eoin O’Connor, Natalie McEvoy, et al.. (2020). Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19. Journal of Cystic Fibrosis. 20(1). 31–35. 13 indexed citations

10.

Franciosi, Alessandro N., Brian D. Hobbs, Oliver J. McElvaney, et al.. (2020). Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory and Critical Care Medicine. 202(1). 73–82. 28 indexed citations

11.

McElvaney, Oliver J., Brian D. Hobbs, Dandi Qiao, et al.. (2020). A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine. 61. 103026–103026. 62 indexed citations

12.

Murphy, Mark P., et al.. (2020). Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis. Frontiers in Pharmacology. 11. 11 indexed citations

13.

Murphy, Mark P., Oisín F. McElvaney, Oliver J. McElvaney, et al.. (2020). α₁Antitrypsin therapy modulates the neutrophil membrane proteome and secretome. European Respiratory Journal. 55(4). 1901678–1901678. 21 indexed citations

14.

McElvaney, Oliver J., Melanie A. Murphy, Oisín F. McElvaney, et al.. (2020). Attitudes of Irish Second-Level Students Towards Vaping. A1080–A1080. 1 indexed citations

15.

McElvaney, Oliver J., Zbigniew Zasłona, Eva M. Pålsson‐McDermott, et al.. (2019). Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 200(11). 1381–1391. 75 indexed citations

16.

Reeves, Emer P., Danielle M. Dunlea, Tomás P. Carroll, et al.. (2019). Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity. The Journal of Immunology. 202(8). 2240–2253. 17 indexed citations

17.

McElvaney, Oliver J., et al.. (2018). Emerging pharmacotherapies in cystic fibrosis. Expert Review of Respiratory Medicine. 12(10). 843–855. 6 indexed citations

18.

McElvaney, Oliver J., Cedric Gunaratnam, Emer P. Reeves, & Noel G. McElvaney. (2018). A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis. Journal of Cystic Fibrosis. 18(2). 203–211. 13 indexed citations

19.

Hurley, Killian, Noreen Lacey, David A. Bergin, et al.. (2014). Alpha-1 Antitrypsin Augmentation Therapy Corrects Accelerated Neutrophil Apoptosis in Deficient Individuals. The Journal of Immunology. 193(8). 3978–3991. 51 indexed citations

20.

Bergin, David A., Emer P. Reeves, Paula Meleady, et al.. (2010). α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. Journal of Clinical Investigation. 120(12). 4236–4250. 224 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact